As of Oct. 31, Zevra has received 90 prescription enrollment forms for MIPLYFFA of which 30% are approved ... MIPLYFFA was further granted Orphan Medicinal Product designation by the European ...
EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...
Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...
Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...
While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...
Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ...
RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.
Amtagvi Infusions: A total of 146 patients have been infused with Amtagvi since the first commercial infusion in April 2024, including 25 patients infused in the second quarter, 82 patients infused in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback